Price movement over the last 24 hours
Ambarella Inc vs Teladoc Health Inc — how do they compare? Ambarella Inc trades at $75.39 (market cap $3.39B), while Teladoc Health Inc trades at $9.2 (market cap $1.68B). The key difference: Ambarella Inc is far larger — about 2× Teladoc Health Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, Ambarella Inc nearer its low. Which is the better fit depends on your goals.
| AMBA | TDOC | |
|---|---|---|
Market Cap | $3.39B | $1.68B |
Sector | Technology | Health |
52-Week High | $95.51 | $9.52 |
52-Week Low | $48.65 | $4.47 |
Enterprise Value | $3.13B | $1.96B |
Signals from Pluang's Aura AI — not financial advice
Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.
Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.
Teladoc Health (TDOC) trades at $9.28, up 0.76% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $2.53B in 2025 with a net loss of $200.32M, though losses are narrowing year-over-year. Recent news highlights expansion through the Walmart partnership and ongoing cost-cutting initiatives. Valuation ratios show a P/S of 0.65 and EV/EBITDA of 9.14, suggesting potential undervaluation relative to sales.
Outlook remains cautious despite improving fundamentals; analyst consensus is mixed with 35.7% buy ratings but a $8.75 price target below current levels. Key risks include persistent net losses, competitive pressures in telehealth, and high debt levels. The stock's trajectory hinges on achieving profitability and sustaining growth amid market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →